During mammalian development, gonadotropin-releasing-hormone-1 neurons (GnRH1ns) migrate from the developing vomeronasal organ (VNO) into the brain asserting control of pubertal onset and fertility. Recent data suggest that correct development of the olfactory ensheathing cells (OEC) is imperative for normal GnRH-1 neuronal migration. However, the full ensemble of molecular pathways that regulate OEC development remains to be fully deciphered. Loss-of-function of the transcription factor Gli3 is known to disrupt olfactory development, however, if Gli3 plays a role in GnRH-1 neuronal development is unclear. By analyzing Gli3 extra-toe mutants (Gli3 Xt/Xt ), we found that Gli3 loss-of-function compromises the onset of achaete-scute family bHLH transcription factor 1 (Ascl-1) positive vomeronasal progenitors and the formation of OEC in the nasal mucosa. Surprisingly, GnRH-1 neurogenesis was intact in Gli3
Introduction
The olfactory placode gives rise to multiple cell types, including migratory/pioneer neurons, terminal nerve cells, gonadotropin releasing hormone-1 (GnRH-1) neurons (GnRH-1ns), olfactory, and vomeronasal sensory neurons (VSNs) (Wray et al., 1989; Miller et al., 2010; Casoni et al., 2016) . GnRH-1ns play a central role in controlling the reproductive axis of vertebrates. During embryonic development olfactory placode derivatives and/or impaired migration of GnRHns. Notably, recent studies show that the ability of the GnRH-1ns to migrate from the olfactory pit to the brain is also critically dependent on the correct development of a specialized neural crest derived glial cells termed "olfactory ensheathing cells" (Barraud et al., 2013; Pingault et al., 2013) . In keeping with this notion, of the known KS genes, two genes, SOX10 and ANOS1 have been recently identified as key factors controlling OECs development (Hu et al., 2019) . Thus, understanding the genetic pathways governing OEC development could provide more mechanistic clues into the basis of aberrant GnRH neuronal migration and therefore, KS.
Gli3, together with Gli1 and Gli2, are key transcription factors involved in the sonic hedgehog (Shh) signaling. In the absence of Shh signaling, Gli3 and Gli2 act as transcriptional repressors. However, in the presence of Shh, Gli1,2 and Gli3 function as transcriptional activators (Sasaki et al., 1999; Niewiadomski et al., 2014) . A spontaneous murine model of the Gli3 gene, Gli3 pdn/pdn has previously implicated a potential role for Gli3 in GnRH neuronal migration. While the hypomorphic Gli3 pdn/pdn model shows a delayed, but not missing, GnRH-1 neuronal migration (Naruse et al., 1994) , the more severe Gli3 null mutants Gli3 extratoe (Gli3 Xt/Xt ) fail to develop a functional olfactory system (Keino et al., 1994; Balmer and LaMantia, 2004; Besse et al., 2011) . However , GnRH1 neuronal development and migration in Gli3 Xt/Xt has not been analyzed.
A candidate gene study in humans has revealed missense variants in the GLI3 gene in HH (Quaynor et al., 2016) but no functional validation has been performed to ascertain the causality of these variants. Furthermore, GLI3 mutations in humans have been reported in non-syndromic forms of polydactyly and syndromic forms of polydactyly of which a subset of patients display neonatal hypogonadism (micropenis and undescended testes) (Johnston et al., 2010) . Despite these observations, the precise role of Gli3 in GnRH neuronal biology remains to be fully elucidated.
By analyzing Gli3
Xt/Xt mutants across the key early developmental stages of embryonic olfactory and GnRH neuronal development, we found that Gli3 loss-offunction compromises the onset of Ascl1+ vomeronasal progenitors and disrupts the formation of OECs in the nasal mucosa. Notably, in Gli3
Xt/Xt , although GnRH-1
Superfrost plus slides (VWR) at 12-16μm thickness for immunostainings and 18-25μm for in situ hybridizations (ISH).
Immunohistochemistry: Primary antibodies and dilutions used in this study were:
goat-α-neuropilin-2 (1:3000, R&D Systems), goat-α-neuorpilin-1 (1:400, R&D Systems), mouse-α-ROBO2(1:50, Santa Cruz) chicken-α-peripherin (1:1500, Abcam), rabbit-α-peripherin (1:2000, Millipore), SW rabbit-α-GnRH-1 (1:6000, Susan Wray, NIH), goat-α olfactory marker protein (1:4000, WAKO), mouse -α-GAD67 (1:200, Santa Cruz), goat-α -AP-2ε (1:1000, Santa Cruz), mouse-α-Meis2 (1:500, Santa Cruz), rabbit-α-phosphoHistone-H3 (1:400, Cell Signaling), rat-α-phospho-Histone-H3 (1:500, Abcam), goat-α-Sox10 (1:100, Santa Cruz), goat-α-collagen IV (1:800, Millipore), goat-α-Gli3 (1:200, R&D Systems), rabbit-α-Hes-1 (1:200, Cell Signaling), and mouse-α-Ascl-1 (1:30, Santa Cruz). Antigen retrieval was performed in a citrate buffer prior to incubation with chicken-α-peripherin, rabbit-α-phospho-Histone-H3, rat-α-phospho-Histone-H3, goat-α-AP-2ε, mouse-α-Meis2, goat-α-Gli3, rabbit-α-Hes-1, mouse-α-Ascl-1, goat-α-Sox10, mouse-α-ROBO2, and mouse-α-GAD67 antibodies. For immunoperoxidase staining procedures, slides were processed using standard protocols (Forni et al., 2013) and staining was visualized (Vectastain ABC Kit, Vector) using diaminobenzidine (DAB) in a glucose solution containing glucose oxidase to generate hydrogen peroxide; sections were counterstained with methyl green. For immunofluorescence, species-appropriate secondary antibodies were conjugated with Alexa-488, Alexa-594, or Alexa-568 (Molecular Probes and Jackson Laboratories) as specified in the legends. Sections were counterstained with 4′,6′-diamidino-2-phenylindole (1:3000; Sigma-Aldrich) and coverslips were mounted with Fluoro Gel (Electron Microscopy Services). Confocal microscopy pictures were taken on a Zeiss LSM 710 microscope. Epifluorescence pictures were taken on a Leica DM4000 B LED fluorescence microscope equipped with a Leica DFC310 FX camera. Images were further analyzed using FIJ/ImageJ software.
Each staining was replicated on at least three different animals for each genotype
In situ hybridization: Digoxigenin-labeled cRNA probes were prepared by in vitro transcription (DIG RNA labeling kit; Roche Diagnostics) from the following templates:
Site directed mutagenesis: The GLI-3 bs-2 plasmid carrying the human GLI3 (Kinzler et al., 1988) was purchased from Addgene. F387F*fs mutation was generated in the vector pCDNA3 hGli3 using Q5 site directed mutagenesis kit (NEB) using primers Gli3
F387Ffs* Fwd CCAACACAGAGGCCTATTCC and Gli3 F387Ffs* Rev AAAGTTGGGGCAGGGTGG following the manufacturer's instruction. Mutation was validated by sequencing prior to use in experiments.
Transfection and luciferase reporter assay: 1x10 4 HeLa cells (ATCC CCL2) were seeded into a 96-well plate 24 hours before transfections. 100 ng of either reporter plasmid (8 X 3 GLI-BS Luc or 8 X 3 Mut GLI-BS Luc) and 100 ng of the effector plasmid (hGli3 WT or F387F*fs) and 20 ng of pRL-SV40 were co-transfected using Lipofectamine 3000 (ThermoFisher). pRL-SV40 coding for Renilla luciferase was used as a transfection control and for normalization. Cells were harvested 48 hours post transfection and Firefly and Renilla luciferase intensities were measured using Glomax 96 microplate luminometer (Promega) and dual-Luciferase Reporter Assay System (Promega).
sequencing (WES) data in the KS cohort was performed on peripheral blood-derived DNA using either Nimblegen SeqCap target enrichment kit (Roche) or a custom Illumina capture kit (ICE) and the detailed variant-calling and annotation used have been described previously (Guo et al., 2018) . WES data were then queried for GLI3 (RefSeq: Statistical Analyses. All statistical analyses were carried out using GraphPad Prism7 software. Cell counts were done on serial sections immunostained for GnRH-1 at E13.5
(n=3) and E15.0 (n=4) and visualized under bright field (immunoperoxidase) or epifluorescence illumination (20×; Leica DM4000 B LED), according to their anatomical location [i.e., (1) nasal region (VNO, axonal tracks surrounding the olfactory pits, forebrain junction); (2) olfactory bulb/fibrocellular mass; and (3) brain (all the cells that accessed the olfactory bulb and were distributed within the forebrain)]. For each animal, counts were performed on 3 serial series. The average number of cells from these 3 series was then multiplied by the total number of series/animal to compute a value for each animal. These were then averaged ± standard error (SE) among animals of the same age and genotype. Means ± SEs were calculated on at least three animals per genotype. The statistical difference between genotypes and groups were determined using an unpaired student's t-test. A gene-based burden testing for human GLI3
variants was performed between the KS and the gnomAD using a Fisher's-exact test.
All data are represented as the mean ±SEM from n≥3 mice per genotype/age for each experiment. Values of p < 0.05 were considered to be statistically significant.
RESULTS

Gli3 is expressed by apical Hes-1+ progenitor cells in the VNO.
Since GnRH-1ns originate in the region of the nasal pit that develops into the vomeronasal organ, we analyzed Gli3 expression throughout GnRH-1ns and VSN development. GnRH-1ns arise between E10.5 and E11.5 and are immunodetectable before vomeronasal neuron formation (Fig.1A ,A1,M,P) (Forni et al., 2011a; Forni et al., 2013; Forni and Wray, 2015; Taroc et al., 2017) . By E13.5 -E15.5, we observed that the developing VNO was populated by Tfap2e (AP-2ε) positive basal VSNs and Meis2 positive apical VSNs (Fig.1N,Q) . However, most GnRH-1ns migrated out of the vomeronasal area by E13.5 (Fig.1B,B1 ,C,C1).
We then performed in-situ hybridization and immunohistochemistry (Data not shown) against Gli3 at embryonic stages E11.5, E13.5, and E15.5 ( Fig.1D-F) . These experiments revealed that Gli3 mRNA and protein mostly localize in the apical regions of the developing vomeronasal epithelia. The proliferative apical cells in the developing olfactory pit (Cuschieri and Bannister, 1975b) localize Hes-1 positive stem cell/progenitors that give rise, over time, to apical Ascl-1 neurogenic progenitors (Cau et al., 2000) . By performing anti phospho-Histone-H3 (PHH3) immunostaining, we only detected mitotic cells in the apical region of the VNO at E11.5. However, at E13.5 and E15.5, we detected mitotic cells along the margins of both the apical and basal regions (Cuschieri and Bannister, 1975a; Cau et al., 2000) ( Fig.1G-I ). Immunostaining for Hes-1
and Ascl-1 in the developing VNO ( Fig.2A-D) showed a progressive enrichment of immune-detectable Ascl1 positive cells over time (Fig.1J-L) . We confirmed opposite expression patterns for Hes-1 and Ascl-1 at E15.5, as Hes-1 localized predominantly in the apical portions and Ascl-1 localized in the basal portions of the developing VNO ( Fig.2A-D) . We confirmed Gli3 immunoreactivity in Hes-1 positive cells and sparse immunoreactivity in the basal regions of the VNO (Fig.2G, H ).
Gli3 loss-of-function affects VSNs neurogenesis but retains VSNs' specification and differentiation.
The expression pattern of Gli3 in apical region of the VNO resembles its expression in the ventricular zone of the developing brain cortex (Hasenpusch-Theil et al., 2018) . Gli3 immunoreactivity in the apical HES1+ proliferative region of the VNO prompted us to analyze if Gli3 repressor activity contributes to initiating the differentiation of neurogenic progenitors (Wang et al., 2011; Hasenpusch-Theil et al., 2018) . We speculated that Gli3 may play a similar role as in the cortex to stimulate the onset of neurogenic progenitors responsible for the genesis of GnRH-1ns, terminal nerve cells, and VSNs. VSNs can differentiate into either apical or basal VSNs (Lin et al., 2018b) . To identify and quantify the cell bodies of the embryonic VSNs, we performed immunolabeling against the transcription factors Meis2 and Tfap2e (AP-2ε) on Gli3 Xt/Xt mutants and controls (Enomoto et al., 2011; Lin et al., 2018a) (Fig.3A,B ). At E15, we detected both apical and basal VSNs in the developing VNOs of controls (Fig.3A) . However, we found a dramatic reduction (~70%) in the number of VSNs in
Gli3
Xt/Xt null mutants. (Fig.3C) . Since we found a significant reduction in proliferation in the basal portions of the VNO, we examined if Gli3 loss-of-function compromised the onset of Ascl-1 positive basal neurogenic progenitors. Quantifying Ascl-1 positive cells confirmed a dramatic (~90%) reduction of Ascl-1+ neurogenic progenitors in the VNO (Fig.3H,I ,E). These data suggest that Gli3 loss-of-function in the VNO impairs the onset of neurogenic progenitors similar to the developing cortex (Wang et al., 2011; Hasenpusch-Theil et al., 2018) . We conclude that the loss of Gli3 mediated gene repression negatively affects the onset of neurogenic progenitors in the VNO.
Gli3 loss-of-function disrupts GnRH-1 neuronal migration.
The observed defects in VSN development prompted us to investigate the impact of Gli3 loss-of-function on GnRH-1 neurogenesis and migration. In control conditions, GnRH-1ns migrate along the axons of the terminal nerve that invade the brain ventral to the olfactory bulb, cross the developing ventral telencephalon/subpallium, then project to the preoptic area (Cariboni et al., 2011; Hanchate et al., 2012; Giacobini and Prevot, 2013; Taroc et al., 2017) (Fig.4A ,C,D,G). However, Gli3
Xt/Xt mutants show large clusters of cells in the nasal area ( Fig.4B,E) , as most GnRH-1ns
were unable to reach the brain. Some GnRH-1ns in these mutants migrated toward the developing brain but then formed cell clumps along the migratory track (Fig.4F ). Sparse
GnRH-1ns did reach the putative forebrain junction without invading the brain (Fig.4B,H ).
We then quantified the distribution of GnRH-1ns between the nasal area forebrain junction and brain on serial parasagittal sections after immuno-staining against GnRH-1 (Fig.4I) . These data revealed a lack of GnRH-1 immunoreactive cells in the brain of Gli3 mutants with a massive accumulation of GnRH-1 cells in the nasal area. We observed a small, but significant, reduction in the number of GnRH-1 positive cells in the brain of heterozygous controls at E15 with a comparable increase in GnRH-1 cells in the nasal area. Notably, quantifying WT, Gli3
Xt/WT data indicate a distinct lineage for VSNs and GnRH-1ns. We propose that Gli3 loss-offunction compromises the formation of Ascl1-1+ vomeronasal progenitors (Fig.3 ), but not GnRH-1 neurogenesis or differentiation.
Gli3 loss-of-function impairs OECs development in the nasal mucosa.
We investigated if the defective migration of GnRH-1ns in Gli3 Xt/Xt results from defective vomeronasal development and/or aberrant terminal nerve projections to the brain. So, we performed a series of immunolabeling experiments to discriminate between cell types. Immunolabeling with anti-peripherin provided a shared marker to highlight olfactory, vomeronasal, and terminal nerve neurons ( GnRH-1 neuronal development strictly depends on correct formation of OECs (Barraud et al., 2013; Pingault et al., 2013) . Gli3 can act as a Sox10 modifier (Matera et al., 2008) . Our data show that Gli3 loss-of-function leads to defective vomeronasal and terminal nerve trajectories, which phenocopies that described after OECs loss in Sox10 null mouse mutants (Barraud et al., 2013; Pingault et al., 2013 ). So, we tested the role of OECs in axonal misrouting and GnRH-1 migratory defects in Gli3
Xt/Xt mutants. So, we performed double staining against Peripherin and Sox10 (Forni et al., 2011b; Pingault et al., 2013; Rich et al., 2018) . In control animals, Sox10 positive OECs were localized proximal to the basal lamina of the vomeronasal epithelium and correlated with the vomeronasal bundles emerging from the vomeronasal epithelium (Fig.5P,R) . In the OE and olfactory fibers, we observed a similar distribution with strong Sox10 immunoreactivity close to the basal regions of the OE and along the olfactory bundles projecting to the OBs (Fig.5P) . In Gli3 Xt/Xt mutants, we found a near complete lack of Sox10 immunoreactivity around the vomeronasal epithelium and no Sox10+ cells associated with vomeronasal axons or terminal nerve (Fig.5Q,S) . We also found no Sox10 immunoreactivity near the basal lamina of the olfactory epithelium (Fig.5Q ).
However, in Gli3
Xt/Xt , we found Sox10 positive ensheathing cells proximal to the brain as part of the FCM (Fig.5Q ), consistent with previous reports (Balmer and LaMantia, 2004 ).
As we detected dramatic defects in OECs formation in the developing olfactory system, we propose that the aberrant neuronal patterning and GnRH-1 migratory impairment observed in Gli3 Xt/Xt mutants is secondary to the lack of OECs in the nasal mucosa (Barraud et al., 2013; Pingault et al., 2013; Rich et al., 2018) .
Delayed, but not defective, migration in Gli3
Xt/WT heterozygous mutants.
Partial defects in GnRH-1 neuronal migration in Gli3 Pdn/Pdn Gli3 hypomorphs (Naruse et al., 1994) suggest that defects in Gli3 levels can impair GnRH-1 neuronal migration. As we collected evidence indicating that Gli3 controls neurogenesis of VSNs, we further analyzed the development of the GnRH-1 system in Gli3 Xt/WT heterozygous embryos. Gli3 Xt/WT are viable and fertile, and have mild craniofacial defects and an extra toe (Veistinen et al., 2012 ). Yet, they do not display dramatic abnormalities in the olfactory system. We analyzed GnRH-1 neuronal migration in Gli3 Xt/WT heterozygous animals after development. Analysis of adult WT controls and Gli3 Xt/WT mutants ( Fig.6A-C ) revealed no significant differences in the number and distribution of GnRH-1ns in the brain after development. Immunostaining against GnRH-1 and quantifying the average area of GnRH-1 immunoreactive axons also revealed comparable GnRH-1 innervation . CC-BY-ND 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint . http://dx.doi.org/10.1101/643155 doi: bioRxiv preprint first posted online May. 20, 2019;  of the median eminence ( Fig.6D-F) . These data suggest that Gli3 haploinsufficiency mice show delayed, but not disrupted, GnRH-1 neuronal migration.
Lack of TN and GnRH-1 invasion of the brain and altered Sema3A expression in
Gli3
Xt/Xt mutants.
In Gli3
Xt/Xt , the few TN and GnRH-1 neurons that reach the brain fail to invade it.
Since brain development can be highly dysmorphic after Gli3 loss-of-function (Aoto et al., 2002; Balmer and LaMantia, 2004; Fotaki et al., 2006; Blaess et al., 2008; Veistinen et al., 2012; Hasenpusch-Theil et al., 2018) , we analyzed how such aberrant development can indirectly compromise the ability of TN and GnRH-1 neurons that do reach the brain to invade it ( Fig 4H; 5K,L). In rodents, gamma-aminobutyric acid (GABA)-ergic interneurons form in the ventral telencephalon and subsequently migrate toward the cortex (Anderson et al., 1997; Lavdas et al., 1999; Wichterle et al., 1999; Wichterle et al., 2001; Markram et al., 2004) . The transcription factor AP-2ε can identify the developing olfactory bulbs and vomeronasal neurons (Feng et al., 2009; Besse et al., 2011; Lin et al., 2018a) (Fig.7A-D) . We used antibodies against glutamate decarboxylase 1 (brain, 67kDa) (GAD67/GAD-1) to label the ventral forebrain/subpallium. Consistent with previous reports (Yu et al., 2009; Besse et al., 2011) , Gli3 Xt/Xt mutants exhibit a lack of rostral olfactory bulb protrusions but form ectopic olfactory bulb-like structures, positive for AP-2ε (Besse et al., 2011) in the dorsal/lateral portions of the developing telencephalon (Fig.7B,D) . At E15.5, GnRH-1ns invade the brain by crossing the putative accumbens (ventral to the OB) and then steering ventrally toward the hypothalamic area.
During embryonic development, Sema3A is expressed ventral to the OB in the putative accumbens/ "septostriatal transition area" (Fig.7E ,G) (Taroc et al., 2017) . Lack of Sema3A is not compatible with normal invasion of the brain by the TN and GnRH-1ns (Cariboni et al., 2011) . As the development of the brain appears highly dysmorphic in Gli3 mutants (See cartoon in 7F), we analyzed the pattern of Sema3A expression compared to controls. Our analysis revealed that Gli3 Xt/Xt mutants showed comparable Sema3A expression to controls in nasal areas and the hindbrain. However, we found a near complete absence of Sema3A expression in the expanded subpallium and the . CC-BY-ND 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint . http://dx.doi.org/10.1101/643155 doi: bioRxiv preprint first posted online May. 20, 2019;  dorsal portion of the forebrain (Fig.7B,D) . These data suggest that Gli3 loss-of-function compromises Sema3A expression and patterning in the brain, which, alone, is a molecular condition sufficient to prevent migratory GnRH-1 neurons to invade the brain (Cariboni et al., 2011; Taroc et al., 2017) .
Ascl-1 loss-of-function compromises VNO and GnRH-1 neurogenesis but retains
OECs formation in the nasal mucosa.
The negative effects of Gli3 loss-of-function on VSNs' but not on GnRH-1ns' neurogenesis prompted us to test if 1) Ascl1 helps control GnRH-1 neurogenesis (Kramer and Wray, 2000; McNay et al., 2006) and 2) the lack of Sox10+ OECs in the mucosa and GnRH-1 migratory phenotype observed in Gli3 mutants directly reflects compromised vomeronasal neurogenesis (Cau et al., 1997; Cau et al., 2002) . We analyzed GnRH-1, VSN, and OECs development at E13.5. At this developmental stage, the TN and VSNs form Peripherin positive fiber bundles that project toward the brain.
We found no effects after loss of one Ascl1 allele on vomeronasal neurogenesis or the number and distribution of GnRH-1ns (Data not shown). However, in Ascl-1 KOs we found a (~60%) reduction in VSNs compared to controls which is similar that in Gli3
Xt/Xt (Fig.8 I, J, O) . As for the reduced neurogenesis, in Ascl-1 null animals we observed a similar (60% ; SE +/-1%; p=0.003) reduction in the number of OECS (Fig.8 K-N,O) .
However, SOX10+ OECs were found to be distributed with similar frequency to the controls along the vomeronasal projections (WT 0.080 cell/μm n=3; Ascl1 KO= 0.082 cell/μm, n=3; p=0.89). In Ascl-1 KOs, we found sparse GnRH-1 immunoreactive neurons emerging from the developing VNO and migrating toward the brain (Fig.8B,D,F,H) . Cell quantifications revealed a significant (~86%) decrease in the total number of GnRH-1 immunoreactive neurons in Ascl-1 KOs (Fig.8P ). As we found no defect in Ascl1+/-but in Ascl1 KOs, our data indicate that Ascl1 has no dose dependent effect on vomeronasal and GnRH-1 neurogenesis (Data not shown).
As we observed a severe reduction in the number of GnRH-1ns in Ascl-1 null, but not in Gli3
Xt/Xt , mutants, our data suggest that the mechanisms controlling Ascl-1 expression in GnRH-1 neuronal progenitors are independent of Gli3 control. Further these observations suggest that the near complete absence of Sox10+ OECs in the nasal mucosa of Gli3
Xt/Xt mutants is not a direct reflection of defective vomeronasal neurogenesis/maturation ( Fig.8O ) (Miller et al., 2018; Rich et al., 2018) , but likely secondary to neural crest defects (Matera et al., 2008) . In support of this conjecture, we observed that Gli3
Xt/WT /Ascl1 +/-double mutants were undistinguishable from Gli3
Xt/WT single mutants (Data not shown).
A GLI3 loss-of-function mutation in a KS and polydactyl patient.
Since KS features reproductive failure and various defects in GnRH-1 neuronal migration, we first examined the genetic constraint for GLI3 gene in Genome et al., 2019) . This population genetics data showed that GLI3 human genetic variants were highly constrained for loss-of-function (frameshifting indel) variant (c.1161del; p.P388Qfs*13; minor allele frequency in gnomAD: 0) in a KS male subject. Since parental DNA samples were not available, the precise mode of inheritance of the variant could not be evaluated.
Additional KS/nIHH gene analysis showed that this KS proband also harbored a heterozygous GNRHR missense mutation (p.Q106R) (Fig.9 ). Since gnomAD variants are not Sanger-confirmed, we performed a gene-based burden test between the KS cohort and gnomAD for all qualifying GLI3 loss-of-function variants that showed enrichment in the KS cohort (p=0.002). We did not observe this enrichment when correcting for Sanger-confirmed variants only in the KS cohort but retaining all unconfirmed gnomAD variants (p=0.06).
The patient harboring the GLI3 loss-of-function variant is a 38-year-old male, who presented to medical attention at age 18 years with anosmia and failure to enter puberty. He was undervirilized with a bilateral low testicular volume (Fig.9 ). His biochemical investigations showed frank hypogonadotropic hypogonadism (serum testosterone: 67 ng/dL; LH: 2.18 mIU/mL and FSH: 3.89 mIU/mL) with neuroendocrine studies revealing low-amplitude low frequency LH pulse profile consistent with hypogonadotropism ( Fig.9 ). The remaining pituitary hormone profile was normal and UPSIT showed complete anosmia. These results confirmed a clinical diagnosis of Kallmann Syndrome. Notably, in line with the well-established role of GLI3 in limb development, he reported in his history an extra toe on his right foot, for which he underwent surgery as a child, and bilateral webbed toes (2 nd and 3 rd toes). Although the precise inheritance mode of the variant was not determined due to lack of parental samples, his mother also exhibited syndactyly affecting her feet, suggesting a possible autosomal dominant mode of inheritance with variable penetrance for the reproductive phenotype ( Fig.9 ).
To test the biological effects of the identified GLI3 variant, we performed a luciferase assay ( acts as a transcriptional repressor in the developing VNO. Notably, Gli3 heterozygous mutant mice showed a small delay in GnRH-1 migration during development without differences in cell number or distribution after birth and were fertile. These data indicate that heterozygous Gli3 loss-of-function mutations, alone, cannot produce a GnRHdeficient state in mice, which is consistent with results from Gli3 hypomorphic mutant mice (Naruse et al., 1994) .
OECs are a glial population that wraps bundles of olfactory and vomeronasal bundles (Rich et al., 2018) . OECs promote normal GnRH-1 neuronal migration from the nasal area to the brain (Barraud et al., 2013; Geller et al., 2013; Pingault et al., 2013) .
OECs arise from the neural crest precursors (Barraud et al., 2010; Forni et al., 2011b; Miller et al., 2016; Miller et al., 2018; Rich et al., 2018) . By analyzing GnRH-1ns migration in Gli3 mutants, we found that most GnRH-1 cells were unable to migrate far from the VNO and formed large clumps of cells on tangled fibers of the putative TN.
This phenotype matches that of Sox10 null mutants (Barraud et al., 2013; Pingault et al., 2013) . Gli3 can act as a Sox10 modifier, which is consistent with the suggestion that OECs surrounding the FCM proximal to the olfactory bulbs. These intriguing data . CC-BY-ND 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint . http://dx.doi.org/10.1101/643155 doi: bioRxiv preprint first posted online May. 20, 2019;  suggest developmental differences between OECs of the nasal mucosa and olfactory bulb OECs (Richter et al., 2005; Ito et al., 2006; Mayeur et al., 2013) .
In Gli3 mutants we found sporadic TN fibers and GnRH-1 cells could reach the brain but not invade it. These findings revealed a similar cellular behavior to that described after Sema3A loss-of-function. Analyses of Gli3
Xt/Xt mutants confirmed very dysmorphic forebrain structures with expanded regions positive for the early subpallial marker, GAD1, and ectopic olfactory bulbs (Balmer and LaMantia, 2004; Fotaki et al., 2006; Blaess et al., 2008; Veistinen et al., 2012) . In-situ hybridization against Sema3A showed a near complete absence of Sema3A expression in the forebrain, a condition that alone is not permissive for normal GnRH-1 migration (Cariboni et al., 2011) . Taken together, we propose that altered Sema3A expression in Gli3 mutants directly reflects either the lack of functional Gli3 transcriptional control or overall aberrant brain development.
Analyzing Ascl-1 null mutants revealed a role for Ascl-1 in controlling GnRH-1 neuronal development, since we found an approximate 86% reduction in the number of GnRH-1 neurons in these mice. We also found no vomeronasal defects together with normal GnRH-1 cell numbers and migration. This finding indicates that Ascl1 is not required in a dose-dependent manner for vomeronasal and GnRH-1 neurogenesis as described for other neurons (McNay et al., 2006) . The lack of overlapping phenotype between Gli3 Xt/Xt (normal GnRH-1 but reduced VSN cell numbers) and Ascl-1 null mutants (reduced GnRH-1 and VSNs cell numbers) indicates that GnRH-1 neurogenic onset is not regulated in a Gli3 dependent fashion.
We observed that OECs defects in Ascl1 mutants appeared less severe than in
Gli3
Xt/Xt and OECs in the mucosa of Ascl1 mutants were positive for Sox10 (Fig. 8O ).
Moreover, Gli3
Xt/WT /Ascl1 +/-double mutants did not have exacerbated phenotypes compared to Gli3 Xt/WT suggesting that the effects seen in both Ascl-1 null and Gli3
Xt/Xt are independent of each other and not additive (data not shown). Taken together, we conclude that the near complete absence of Sox10+ immunoreactivity in the nasal mucosa of Gli3 Xt/Xt mutants is not secondary to the decreased number of vomeronasal fibers (Miller et al., 2018) .
We identified a novel GLI3 frameshifting loss-of-function variant in a KS proband.
Using site-directed mutagenesis and luciferase assays, we confirmed a loss of . CC-BY-ND 4.0 International license It is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
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OECs around the VNO, ****p<0.000. Scale bars are all 100 μm.
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